Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
- Nichi-Iko Pres. Airs Frustration with Sanofi over Cancellation of Biosimlar Codevelopment Deal
November 8, 2013
- Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
- Bristol-Myers Files NDA for DCV/ASV Combination Therapy for Treatment of Hepatitis C in Japan
November 8, 2013
- MTPC Aims to Reach Midterm Targets through Royalties from Licensed Products, But Success Likely to Depend on Performance in Domestic Market
November 8, 2013
- Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes
November 6, 2013
- Safety Profile Holds Key to Triumph of Edoxaban: Daiichi Sankyo President
November 6, 2013
- Daiichi Sankyo President Apologizes Over Ranbaxy Problem, Pledges to Resolve Issue by Dispatching Employees
November 6, 2013
- Takeda to Cut Costs by 100 Billion Yen, Reduce Workforce by Below 5%
November 5, 2013
- Growth-Engine Drugs Jack Up Eisai Sales in April-September; Aricept’s Japan Target within Sight
November 5, 2013
- Astellas Plans to Tap 300 Workers in Japan for Early Retirement in FY2014
November 5, 2013
- Astellas 1st Half Operating Profit Down 4.4% on Higher Sales
November 5, 2013
- Shionogi Logs Record Profits in April-September on Rigid Cost Control
November 1, 2013
- Daiichi Sankyo Sales Up 7% Thanks to Nexium, Ranbaxy Posts Net Loss
November 1, 2013
- Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
- Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan
October 31, 2013
- Teva Pharma Japan Notifies Customers of Stock-Out of Mucosolate L Cap.45, Lemalc Tab. 100 Due to Manufacturing Troubles
October 30, 2013
- Taiwan Approval Sought for DSP’s Antipsychotic Lurasidone
October 30, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…